Path ID: DB04878_MESH_D005776_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C102817 | voglibose | Drug |
| MESH:D005963 | Glucosylceramides | ChemicalSubstance |
| MESH:D005776 | Glucosylceramide beta-glucosidase deficiency | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Voglibose | INCREASES DEGRADATION OF | Glucosylceramides |
| Glucosylceramides | CAUSES | Glucosylceramide Beta-Glucosidase Deficiency |
Comment: No direct evidence available that support voglibose MoA for Gaucher Disease. However there is a hypothesis that the combination of small α-glucosidase inhibitors as pharmacological chaperones (PCs) with enzyme replacement therapy (ERT) has been shown to have a synergic effect in improved enzyme activity and reduction of toxic metabolites in Pompe’s disease or Gaucher disease.
Reference: